IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability

Ebola virus (EBOV) is one of the most virulent pathogens that causes hemorrhagic fever and displays high mortality rates low prognosis in both humans nonhuman primates. The post-exposure antibody therapies to prevent EBOV infection are considered effective as yet. However, owing poor thermal stability mammalian antibodies, their application tropics has remained limited. Therefore, a thermostable therapeutic against was developed modelled on poultry(chicken) immunoglobulin Y (IgY). IgY antibodies retaining neutralising activity at 25°C for year, displayed excellent stability, opposed conventional polyclonal (pAbs) or monoclonal (mAbs). Laying hens were immunised with variety vaccine candidates it confirmed VSVΔG/EBOVGP encoding glycoprotein could induce titer EBOV. efficacy immune vivo evaluated newborn Balb/c mice who have been challenged model. Mice lethal dose pseudovirus treated 2 24 h post-infection different doses anti-EBOV IgY. group receiving 10 6 NAU/kg (neutralising units/kilogram) showed complete protection no symptoms disease, while low-dose only partially protected. Conversely, all naive died within days. In conclusion, exhibits thermostability protective efficacy. Anti-EBOV shows lot promise entering realm efficient treatment regimens.